These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

301 related items for PubMed ID: 15729083

  • 1. The relationship between early changes in the HAMD-17 anxiety/somatization factor items and treatment outcome among depressed outpatients.
    Farabaugh A, Mischoulon D, Fava M, Wu SL, Mascarini A, Tossani E, Alpert JE.
    Int Clin Psychopharmacol; 2005 Mar; 20(2):87-91. PubMed ID: 15729083
    [Abstract] [Full Text] [Related]

  • 2. A Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder.
    Fava M, Alpert J, Nierenberg AA, Mischoulon D, Otto MW, Zajecka J, Murck H, Rosenbaum JF.
    J Clin Psychopharmacol; 2005 Oct; 25(5):441-7. PubMed ID: 16160619
    [Abstract] [Full Text] [Related]

  • 3. Anxious depression and early changes in the HAMD-17 anxiety-somatization factor items and antidepressant treatment outcome.
    Farabaugh AH, Bitran S, Witte J, Alpert J, Chuzi S, Clain AJ, Baer L, Fava M, McGrath PJ, Dording C, Mischoulon D, Papakostas GI.
    Int Clin Psychopharmacol; 2010 Jul; 25(4):214-7. PubMed ID: 20400905
    [Abstract] [Full Text] [Related]

  • 4. Do early changes in the HAM-D-17 anxiety/somatization factor items affect the treatment outcome among depressed outpatients? Comparison of two controlled trials of St John's wort (Hypericum perforatum) versus a SSRI.
    Bitran S, Farabaugh AH, Ameral VE, LaRocca RA, Clain AJ, Fava M, Mischoulon D.
    Int Clin Psychopharmacol; 2011 Jul; 26(4):206-12. PubMed ID: 21278577
    [Abstract] [Full Text] [Related]

  • 5. Fluoxetine treatment of depressed patients with comorbid anxiety disorders.
    Sonawalla SB, Farabaugh A, Johnson MW, Morray M, Delgado ML, Pingol MG, Rosenbaum JF, Fava M.
    J Psychopharmacol; 2002 Sep; 16(3):215-9. PubMed ID: 12236627
    [Abstract] [Full Text] [Related]

  • 6. Continuation and long-term maintenance treatment with Hypericum extract WS 5570 after recovery from an acute episode of moderate depression--a double-blind, randomized, placebo controlled long-term trial.
    Kasper S, Volz HP, Möller HJ, Dienel A, Kieser M.
    Eur Neuropsychopharmacol; 2008 Nov; 18(11):803-13. PubMed ID: 18694635
    [Abstract] [Full Text] [Related]

  • 7. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I.
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [Abstract] [Full Text] [Related]

  • 8. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms.
    Davidson JR, Meoni P, Haudiquet V, Cantillon M, Hackett D.
    Depress Anxiety; 2002 Dec; 16(1):4-13. PubMed ID: 12203668
    [Abstract] [Full Text] [Related]

  • 9. Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder.
    Papakostas GI, McGrath P, Stewart J, Charles D, Chen Y, Mischoulon D, Dording C, Fava M.
    Psychiatry Res; 2008 Oct 30; 161(1):116-20. PubMed ID: 18755514
    [Abstract] [Full Text] [Related]

  • 10. Anxiety does not predict response to duloxetine in major depression: results of a pooled analysis of individual patient data from 11 placebo-controlled trials.
    Nelson JC.
    Depress Anxiety; 2010 Oct 30; 27(1):12-8. PubMed ID: 20013987
    [Abstract] [Full Text] [Related]

  • 11. Early improvement in HAMD-17 and HAMD-6 scores predicts ultimate response and remission for depressed patients treated with fluoxetine or ECT.
    Lin HS, Lin CH.
    J Affect Disord; 2019 Feb 15; 245():91-97. PubMed ID: 30368075
    [Abstract] [Full Text] [Related]

  • 12. Early improvement in HAMD-17 and HAMD-7 scores predict response and remission in depressed patients treated with fluoxetine or electroconvulsive therapy.
    Lin CH, Park C, McIntyre RS.
    J Affect Disord; 2019 Jun 15; 253():154-161. PubMed ID: 31035216
    [Abstract] [Full Text] [Related]

  • 13. Hypericum extract in patients with MDD and reversed vegetative signs: re-analysis from data of a double-blind, randomized trial of hypericum extract, fluoxetine, and placebo.
    Murck H, Fava M, Alpert J, Nierenberg AA, Mischoulon D, Otto MW, Zajecka J, Mannel M, Rosenbaum JF.
    Int J Neuropsychopharmacol; 2005 Jun 15; 8(2):215-21. PubMed ID: 15458612
    [Abstract] [Full Text] [Related]

  • 14. Cluster analysis of symptoms during antidepressant treatment with Hypericum extract in mildly to moderately depressed out-patients. A meta-analysis of data from three randomized, placebo-controlled trials.
    Kasper S, Dienel A.
    Psychopharmacology (Berl); 2002 Nov 15; 164(3):301-8. PubMed ID: 12424554
    [Abstract] [Full Text] [Related]

  • 15. Health-related quality of life and symptom severity in Chinese patients with major depressive disorder.
    Cao Y, Li W, Shen J, Malison RT, Zhang Y, Luo X.
    Asia Pac Psychiatry; 2013 Dec 15; 5(4):276-83. PubMed ID: 23857826
    [Abstract] [Full Text] [Related]

  • 16. A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression.
    Fava M, Schaefer K, Huang H, Wilson A, Iosifescu DV, Mischoulon D, Wessel TC.
    J Clin Psychiatry; 2011 Apr 15; 72(4):473-9. PubMed ID: 21208574
    [Abstract] [Full Text] [Related]

  • 17. The efficacy and tolerability of once-daily controlled-release trazodone for depressed mood, anxiety, insomnia, and suicidality in major depressive disorder.
    Sheehan DV, Rozova A, Gossen ER, Gibertini M.
    Psychopharmacol Bull; 2009 Apr 15; 42(4):5-22. PubMed ID: 20581790
    [Abstract] [Full Text] [Related]

  • 18. Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression.
    Fava M, Rosenbaum JF, Hoog SL, Tepner RG, Kopp JB, Nilsson ME.
    J Affect Disord; 2000 Aug 15; 59(2):119-26. PubMed ID: 10837880
    [Abstract] [Full Text] [Related]

  • 19. Hypericum extract LI 160 and fluoxetine in mild to moderate depression: a randomized, placebo-controlled multi-center study in outpatients.
    Bjerkenstedt L, Edman GV, Alken RG, Mannel M.
    Eur Arch Psychiatry Clin Neurosci; 2005 Feb 15; 255(1):40-7. PubMed ID: 15538592
    [Abstract] [Full Text] [Related]

  • 20. A randomized double-blind clinical trial on analgesic efficacy of fluoxetine for persistent somatoform pain disorder.
    Luo YL, Zhang MY, Wu WY, Li CB, Lu Z, Li QW.
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Nov 13; 33(8):1522-5. PubMed ID: 19733606
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.